QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
📊Multiple sclerosis, EBV & Nordic data recognised at ECTRIMS
Excited to share that our Danish-Swedish real-world study has been selected for the 𝟐𝟎𝟐𝟓 𝐁𝐞𝐬𝐭 𝐨𝐟 𝐄𝐂𝐓𝐑𝐈𝐌𝐒 slide deck – highlighting it as one of this year’s top abstracts.
The abstract, co-authored by Jonas Banefelt and Mathias Lilja, explores the link between Epstein-Barr virus-induced mononucleosis and the later risk of multiple sclerosis, using nationwide observational data.
We’re proud to see this collaboration with Moderna and our methodological work recognised at such […]
The largest multiple sclerosis conference in the world, ECTRIMS is approaching!
Quantify Research is part of the program this year in Barcelona:
-Kelsi Smith (Quantify Research) presents poster P628 on “Sex differences in the association of the melanocortin-1 receptor (MC1R) gene with multiple sclerosis risk”, research of hers from her PhD.
From 1 September 2025, companies must notify the DMP (NOMA) three months in advance before submitting STA documentation
See what else will change below 👇
The DMP has published updated requirements for the single technology assessment (STA) submission process, applying to both reimbursement and hospital medicines, effective from 1 September 2025.
Key changes:
• 🗓 Companies must notify the DMP of their intended STA submission week at least three months in advance
• 👩⚕️ Earlier recruitment of medical experts will begin upon notification
• 📑 More formal and enforceable standards for the […]
Economic burden of narcolepsy: new study published
Quantify Research has co-authored a new paper on the health care and productivity costs of narcolepsy, using comprehensive Swedish registry data.
The study matched incident narcolepsy patients to controls by age and sex to isolate the disease burden.
The study’s findings included:
👉2–5x higher use of inpatient, outpatient, and pharmaceutical care
👉Significantly more days on sick leave and disability leave
The results point to a substantial economic […]